Exact Sciences Corporation

Financials

Overview Estratto Conto Statistics Dividends

Cash from operating activities 136.48 M-102.24 M-223.56 M156.12 M210.54 M491.44 M 491.44 M Cash from investing activities -702.04 M-1.08 B74.07 M49.68 M-442.15 M195.12 M 195.12 M Cash from financing activities 1.88 B8.47 M76.48 M159.77 M231.87 M-338.09 M -338.09 M Free cash flow 72.13 M-238 M-438.02 M31.93 M74.55 M356.78 M 356.78 M

Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer. In November 2025, Abbott Laboratories agreed to acquire Exact Sciences in a deal worth roughly $21 billion.

EXAS

Financials

Exact Sciences Corporation

Notizie

Exact Sciences stock hits 52-week high at $103.55

Exact Sciences shareholders approve merger with Abbott Laboratories

Gli azionisti di Exact Sciences approvano l’acquisizione da parte di Abbott

Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up

CSLLY vs. EXAS: Which Stock Is the Better Value Option?

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates

Soft Start For $10B-Plus M&A Deals In 2026

Stabilito un percorso di copertura Medicare per i test di rilevamento multi-cancro

Medicare coverage pathway established for multi-cancer detection tests

Il titolo di Exact Sciences tocca il massimo di 52 settimane a $102,69

Exact Sciences stock hits 52-week high at $102.69